New drug combo could make inoperable kidney tumors removable

NCT ID NCT06794229

Recruiting now Disease control Sponsor: Qian Qin Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 19 times

Summary

This study tests whether a 12-week course of zanzalintinib (a pill) plus nivolumab (an immunotherapy) can shrink advanced kidney tumors enough to allow surgery. About 69 adults with locally advanced or inoperable clear cell renal cell carcinoma will receive the combination. After 12 weeks, scans will determine if the tumor can be removed; if not, treatment may continue for up to 48 weeks. The goal is to improve surgical options and control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RENAL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED RENAL CELL CARCINOMA